Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
52.64M
Cash
30.9M
Avg Qtr Burn
-5.307M
Short % of Float
8.33%
Insider Ownership
12.13%
Institutional Own.
12.92%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab Details Cancer, Platinum-resistant ovarian cancer, Ovarian cancer | Phase 3 Data readout | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Small cell lung cancer | Phase 2 Data readout |